Panacea Pharmaceuticals, Inc. Appoints ChristopherKircher, M.D. as Chair of Medical Advisory...

Business Editors & Health/Medical Writers

BIOWIRE2K

ROCKVILLE, Md.--(BW HealthWire)--July 7, 2000

Panacea Pharmaceuticals, Inc. is pleased to announce that it has appointed Christopher Kircher, M.D. as Chairman of its Medical Advisory Board.

Dr. Kircher

Dr. Kircher is currently the principal investigator for on-going clinical trials in multiple sclerosis, migraine, and others. He is the originator and principal investigator for the Community Hypertension Screening Program at the Linder Center for Cardiovascular Research as well as an investigator and neurologist for the carotid artery angioplasty and stenting study at the Christ Hospital in Cincinnati.

Dr. Kircher is a frequent invited speaker and lecturer for companies such as Glaxo-Wellcome, Novartis, Biogen, and Merck on subjects ranging from Alzheimer's disease to hypertension to Parkinson's disease.

Dr. Kircher has served or currently serves as a consultant or advisor to Novartis, Merck, and Glaxo-Wellcome. He is a medical advisory board member for Auburn Medical Imaging. Dr. Kircher was formerly Chair of the Medical Advisory Board for Nymox Corporation and currently holds this position for Alzheimer's Corporation.

Dr. Kircher received his medical degree from Indiana University School of Medicine and completed his internship at St. Joseph Infirmary in Louisville, a junior neurology residency at the University of Minnesota Affiliated Hospitals, and senior and chief residencies in neurology at the University of Cincinnati Medical Center. Dr. Kircher is board certified and licensed in both Ohio and Kentucky.

"The addition of Dr. Kircher is an honor and a pleasure for us at Panacea," said Hossein A. Ghanbari, Ph.D., President and CEO of Panacea. "With Chris' leadership and guidance, we will be able to quickly expand our Medical Advisory Board's membership and move towards a representative and formidable team that will effectively interface with neurologists and other specialists."

Dr. Kircher stated, "It's a real thrill to be working with Panacea's excellent team in support of its cutting-edge and compelling technology. I'm particularly excited at being involved in and contributing to Panacea's Alzheimer's disease projects, which have been developed by some of the field's top minds and have been finely integrated to provide real promise towards the treatment of this horrible disease."

About Panacea Pharmaceuticals

Panacea Pharmaceuticals, Inc. focuses on developing and utilizing protein-based technologies to detect and identify changes associated with and involved in diseases of the central nervous system such as Alzheimer's disease, brain tumors, transmissible spongiform encephalopathies, and Lewy body diseases such as Parkinson's disease.

Changes in disease-relevant proteins by altered expression, post-translational modification, and functional variation are utilized to develop diagnostic tests and therapeutic agents.

More information is available at www.PanaceaPharma.com, a web site developed by Ei Web Promotion, a division of eiCommunications.com, Inc. (www.eiCommunications.com), which offers integrated communications and web development solutions for the Information Age.